Who is sponsoring NCT05360160?

NCT05360160 is sponsored by M.D. Anderson Cancer Center.

What condition does NCT05360160 study?

NCT05360160 studies Acute Myeloid Leukemia.

What drugs are being tested in NCT05360160?

Interventions: SNDX-5613, Venetoclax, ASTX727.

What is the status of NCT05360160?

NCT05360160 is currently RECRUITING.

Last reviewed 2026-04-14 · How we verify

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

NCT05360160 PHASE1, PHASE2 RECRUITING

Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL). Part 2 of this study is to learn if the dose of study drugs found in Part 1b can help to control AML/MPAL

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	PHASE1, PHASE2
Status	RECRUITING
Enrolment	43
Start date	Fri Oct 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Acute Myeloid Leukemia

Interventions

SNDX-5613
Venetoclax
ASTX727

Countries

United States